



## Curriculum Vitae

### Personal information Andre Berger

#### Work experience

---

1. Employer: Paul\_Ehrlich\_Institut
  - Start date: 2015
  - End date: present
  - Position: Senior Policy Adviser;
  - Activities: HMA and EMA MB-related activities, Head of Innovation Office
  - Country: Germany
2. Employer: Paul\_Ehrlich\_Institut
  - Start date: 2010
  - End date: 2015
  - Position: ATMP Assessor for Q and NC Data
  - Activities: Assessment in EU- and national ATMP regulatory procedures
  - Country: Germany
3. Employer: Paul\_Ehrlich\_Institut
  - Start date: 2007
  - End date: 2010
  - Position: Scientific Associate
  - Activities: Basic Research in Stem Cell Biology & Virus\_Host Interaction; Education in ATMP Assessment
  - Country: Germany
4. Employer: Sanofi\_Aventis Deutschland GmbH
  - Start date: 2006
  - End date: 2007
  - Position: Grad Student
  - Activities: Cell\_Based Assay Development
  - Country: Germany

#### Education and training

---

1. Subject: University of Applied Sciences Apollon Hochschule der Gesundheitswirtschaft Bremen
  - Start date: 2016
  - End date: 2021
  - Qualification: Master of Health Economics
  - Organisation:
  - Country: Germany
2. Subject: University of Frankfurt
  - Start date: 2007
  - End date: 2010
  - Qualification: PhD
  - Organisation:
  - Country: Germany
3. Subject: University of Frankfurt
  - Start date: 2002
  - End date: 2006
  - Qualification: Certified biologist
  - Organisation:
  - Country: Germany

#### Additional information

---

##### Publications

SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez\_Sesma A, Rutsch F, Simon V, König R, Flory E. PLoS Pathog. 2011 Dec;7(12):e1002425. Epub 2011 Dec 8. Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer. Hlavaty J, Petznek H, Holzmüller H, Url A, Jandl G, Berger A, Salmons B, Günzburg WH, Renner M. PLoS One. 2012;7(7):e40611. Epub 2012 Jul 16. PKC $\delta$ -induced PU.1 phosphorylation promotes hematopoietic stem cell differentiation to dendritic cells. Hamdorf M, Berger A, Schüle S, Reinhardt J, Flory E. Stem Cells. 2011 Feb;29(2):297-306. doi: 10.1002/stem.564. The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises. Berger A, Schüle S, Flory E. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):816-21. Review. German. Interaction of Vpx and apolipoprotein B mRNA editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. Berger A, Münk C, Schweizer M, Cichutek K, Schüle S, Flory E. J Biol Chem. 2010 Apr 16;285(16):12248-54. doi: 10.1074/jbc.M109.090977. Mutation of a diacidic motif in SIV\_PBJ Nef impairs T<sub>H</sub> cell activation and enteropathic disease. Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuß H, Hamdorf M, Schweizer M, Cichutek K, Flory E. Retrovirology. 2011 Mar 2;8:14. doi: 10.1186/1742-4690-8-14.

##### Projects

##### Memberships

##### Other Relevant Information